GfK CEO snags lifetime achievement award

Share this article:

Richard Vanderveer, PhD, group CEO, GfK US Healthcare Companies, accepted a lifetime achievement award last month from the Pharmaceutical Business Intelligence and Research Group (PBIRG).

The award recognizes Vanderveer’s 35-year career in the pharmaceutical industry.
Over the next five years, pharmaceutical marketing researchers should help reinvent the pharmaceutical industry, which is in “rather dire straits,” Vanderveer said in his acceptance speech at PBIRG’s annual conference in Savannah, GA. “We now must turn our attention to helping the industry develop a more effective, efficient way of communicating with our key stakeholders.”


Vanderveer, whose column, “Vantage Point,” appears on MM&M’s new Marketing Research page, taught the industry to use Individual Physician Level Prescribing Data (IPLRx) in the early 1990s. His contributions also include pioneering several new marketing research methodologies, developing numerous training programs and founding several successful marketing research organizations.


Past recipients of the PBIRG award have included Alice Burstein of Pfizer, Alan Bowditch of Martin Hamblin and Cliff Kalb, formerly of Merck.

Share this article:

Email Newsletters

More in News

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi and partner Regeneron attached a $67.5-million priority review voucher to their experimental cholesterol drug alirocumab, making for a tighter race with Amgen.

HHS shows how diabetes adds up

HHS shows how diabetes adds up

A 2005-to-2010 survey shows diabetics 65-and-up juggle at least four co-morbid conditions and five medications for them.

AstraZenca beefs up respiratory portfolio

AstraZenca beefs up respiratory portfolio

AstraZeneca has made an $875-million move to beef up its respiratory pipeline by making Almirall's lineup its own.